GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (OTCPK:ABCZF) » Definitions » Loans Receivable

Abcam (ABCZF) Loans Receivable : $0.0 Mil (As of Jun. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Abcam Loans Receivable?

Abcam's Loans Receivable for the quarter that ended in Jun. 2023 was $0.0 Mil.


Abcam Loans Receivable Historical Data

The historical data trend for Abcam's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam Loans Receivable Chart

Abcam Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec22
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abcam Semi-Annual Data
Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Jun22 Dec22 Jun23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Abcam Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Abcam Loans Receivable Related Terms

Thank you for viewing the detailed overview of Abcam's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Abcam (ABCZF) Business Description

Traded in Other Exchanges
N/A
Address
Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX
Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.